SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

Correspondence 0001104659-23-111752 from Cellectar Biosciences, Inc. (CLRB)

Cellectar Biosciences, Inc.
Date: Oct. 26, 2023 · CIK: 0001279704 · Accession: 0001104659-23-111752

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-274880

Date
October 26, 2023
Author
/s/ Chad J. Kolean
Form
CORRESP
Company
Cellectar Biosciences, Inc.

Letter

CELLECTAR BIOSCIENCES, INC.

100 Campus Drive

Florham Park, New Jersey 07932

October 26, 2023

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Ms. Cindy Polynice

Re: Acceleration Request for Cellectar Biosciences, Inc.

Registration Statement on Form S-3 (File No. 333-274880)

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc. (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-274880 (the “Registration Statement”) be accelerated so that the Company’s Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on October 30, 2023, or at such later time as the Company or its counsel may request from the staff of the Division of Corporation Finance of the U.S. Securities and Exchange Commission.

We would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin LLP at (212) 839-5651 or ihajdu@sidley.com.

Very truly yours,
/s/ Chad J. Kolean

Show Raw Text
CORRESP
1
filename1.htm

CELLECTAR BIOSCIENCES, INC.

100 Campus Drive

Florham Park, New Jersey 07932

October 26, 2023

Via EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549-3720

Attention: Ms. Cindy Polynice

Re: Acceleration Request for
Cellectar Biosciences, Inc.

Registration Statement on Form
S-3 (File No. 333-274880)

Ladies and Gentlemen:

Pursuant
to Rule 461 under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc. (the “Company”),
hereby requests that the effective date of the Company’s Registration Statement on Form S-3, Registration Number 333-274880 (the
 “Registration Statement”) be accelerated so that the Company’s
Registration Statement will become effective at 4:00 P.M., Eastern Time or as soon thereafter as practicable, on October 30, 2023, or
at such later time as the Company or its counsel may request from the staff of the Division of Corporation Finance of the U.S. Securities
and Exchange Commission.

We
would appreciate it if, as soon as the Registration Statement is declared effective, you would so inform Istvan A. Hajdu of Sidley Austin
LLP at (212) 839-5651 or ihajdu@sidley.com.

    Very truly yours,

    /s/ Chad J. Kolean

    Chad J. Kolean

    Chief Financial Officer

    cc:
    James V. Caruso

    Asher M. Rubin

    Istvan A. Hajdu

    Kostian Ciko